Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity
about
The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytesNectin-2 is a potential target for antibody therapy of breast and ovarian cancersProduction of monoclonal antibodies in plants for cancer immunotherapyEnhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.Protein engineering of antibodies.High affinity mouse-human chimeric Fab against hepatitis B surface antigen.Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection.Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients.Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodyniaChimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacyHuman immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancerInfluence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.Phosphatidylserine exposure on the surface of Leishmania amazonensis amastigotes modulates in vivo infection and dendritic cell function.IgG4 subclass antibodies impair antitumor immunity in melanoma.IgE immunotherapy: a novel concept with promise for the treatment of cancer.Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors.Monoclonal antibodies in diagnosis and therapy.Treatment of high-risk neuroblastoma with anti-GD2 antibodies.Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.Deglycosylation of mAb by EndoS for improved molecular imaging.Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion moleculeRecombinant antibody technology: its advent and advances.Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.Antibody dependent cell-mediated cytotoxicity using hepatocellular carcinoma reactive monoclonal antibody.On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay.Expression and characterization of a recombinant porcinized antibody against the E2 protein of classical swine fever virus.A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis.Effector cell analysis of human multidrug-resistant cell killing by mouse-human chimeric antibody against P-glycoprotein.Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein.Development and characterization of chimeric anti-carcinoembryonic antigen monoclonal antibodies and their Fab fragments.Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer.Affinity of human IgG subclasses to mouse Fc gamma receptors.Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancerIn‐Tandem Column Arrangement for Rapid Purification of IgG using a Blue Avid Gel P and an Aza‐Arenophilic Affinity Gel
P2860
Q22008474-BFF7CDAB-1650-43DE-8545-252BFA76407DQ24294932-E3CDADB4-3C46-42F8-8112-6B7313A8E6E2Q26778423-3855F141-FA94-4E94-9CE8-81A832959BD4Q30224854-4243BBA4-E82D-49A2-A61E-BBE920200C94Q30657795-1AE7698D-D972-4523-92ED-0A370793C091Q33192279-5D74985E-4C9B-4B89-8A3B-597B43BC0B09Q33232511-A7E21B63-2EB5-49FA-ABDA-8A0AD3041721Q33820823-A6CB2F95-79AB-462D-8BC8-55D31B56BC4CQ33885996-B4CB5071-ACFB-497A-9E48-D002B93C26DAQ35092616-1BE5AD56-0CB9-4E9A-AF7F-437FE463F5D0Q35399080-9642F3EC-89CA-4C21-93E7-24C22A4ED9CBQ35689463-6029E658-57E8-4F13-98B8-6EAED8CF3BEFQ36079704-0422CCA7-51DC-49B5-A48C-13DBB01B8552Q36513475-08F70D2A-7B5B-4086-9DCC-44F17E303C31Q36589026-2FDC8AAB-7F8D-405C-A064-54426D7FCF57Q36733452-3E6738AF-3055-453B-90D1-C3413ED66A6EQ37593712-463BF49B-ED5F-4F23-A516-2D9B45327509Q37646545-8301779F-47E8-4004-A8EC-D2A256E8247EQ37755851-DC0AA6C6-E061-441A-9D5B-7B3E24D20C11Q37820755-A47D508A-0074-4079-8F82-1CA3B0A120C6Q38662532-A0797D4D-33EA-46A4-A111-DBD411176711Q38880179-23B4A0FC-F79A-4DB7-9E92-02E4745EE627Q38964828-40169D6F-A879-4DDB-94A9-1589F46A5872Q39114747-37A1600D-AD30-458A-9959-4CBC36A93D07Q39708585-D8BEFC02-28BE-4DF0-A33C-DC83D148E310Q40661240-04C0D535-2101-4787-BAD1-B1DFE317877EQ40771987-14A38900-DE50-4E91-AC7B-2EEB40782916Q40801062-C5905C6D-8D83-4978-956D-C8160BF7C8F1Q40957892-E374F295-0EC0-4C9E-9574-896984F63A8FQ41020898-E9DB37AA-FCA4-4051-B03C-E8E1800AE22AQ41868216-9CAC22DD-38A7-4BD6-BB80-680E2906785BQ45324116-C4B07814-6842-425F-A410-E7BE8A0ED708Q52881780-90B58E3C-6719-410F-A09F-B0A5135F6189Q54269812-B914B85D-0480-42A5-98E8-0380AE94C019Q54271615-33C9583B-8634-4B2E-B955-78D0376E4C70Q54638254-4CE5205E-2490-488B-AB2C-F7DEC13CA28FQ55035074-B39F355D-04ED-47F9-9E60-CA430450FCD6Q55116109-BF38BF98-A0C5-4659-9AE3-EAD547508FA7Q57694335-D7BA55C5-9BEB-430C-ADB3-D3E4D3410AE9Q58274133-FA9FF1D5-9BAB-4369-A5ED-9240EFF20F9F
P2860
Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity
description
1988 nî lūn-bûn
@nan
1988 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Biological activity of human-m ...... ies with antitumor specificity
@ast
Biological activity of human-m ...... ies with antitumor specificity
@en
Biological activity of human-m ...... es with antitumor specificity.
@nl
type
label
Biological activity of human-m ...... ies with antitumor specificity
@ast
Biological activity of human-m ...... ies with antitumor specificity
@en
Biological activity of human-m ...... es with antitumor specificity.
@nl
prefLabel
Biological activity of human-m ...... ies with antitumor specificity
@ast
Biological activity of human-m ...... ies with antitumor specificity
@en
Biological activity of human-m ...... es with antitumor specificity.
@nl
P2093
P2860
P356
P1476
Biological activity of human-m ...... ies with antitumor specificity
@en
P2093
C W Shearman
H Koprowski
Z Steplewski
P2860
P304
P356
10.1073/PNAS.85.13.4852
P407
P577
1988-07-01T00:00:00Z